Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Unity Biotechnology

Unity Biotechnology
2009 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
UBX STOCK SYMBOL
$8.04 SHARE PRICE (As of Thursday Closing)
Description

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and designs senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as arthritis, vision loss and cognitive decline.

Formerly Known As
Cenexys
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 3280 Bayshore Boulevard
  • Brisbane, CA 94005
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Unity Biotechnology’s full profile, request a free trial.

Unity Biotechnology Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$7.39 - $24.56 $345M $8.71 -$2.06 194K 42.9M

Unity Biotechnology Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 176,435 601,655
Revenue 0 0 1,382 0
EBITDA (80,682) (77,530) (44,407) (28,068)
Net Income (79,031) (76,398) (44,656) (30,404)
Total Assets 160,797 181,375 102,024 96,648
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Unity Biotechnology Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Unity Biotechnology‘s full profile, request access.

Request full access to PitchBook

Unity Biotechnology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Unity Biotechnology‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Unity Biotechnology Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Recyte Therapeutics Angel-Backed Alameda, CA 000.00 0000000000 000.00
000000000 Formerly VC-backed Boston, MA 00 00000 00000000 00000
000000 Corporation Honolulu, HI 00 000.00 000000000 000.00
To view this company’s complete list of competitors, request access »

Unity Biotechnology Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Unity Biotechnology‘s full profile, request access.

Request full access to PitchBook

Unity Biotechnology Executive Team (21)

Name Title Board
Seat
Contact
Info
Keith Leonard Jr. Chairman & Chief Executive Officer
Nathaniel David Ph.D Co-Founder, Board Member & President
Bob Goeltz Chief Financial Officer
Dan Marquess Chief Scientific Officer
Daohong Zhou MD Co-Founder

1 Former Executive

You’re viewing 5 of 21 executives. Get the full list »

Unity Biotechnology Board Members (7)

Name Representing Role Since Contact
Info
Camille Samuels Venrock Board Member 000 0000
David Lacey MD Self Board Member 000 0000
Graham Cooper Self Board Member 000 0000
Keith Leonard Jr. Unity Biotechnology Chairman & Chief Executive Officer 000 0000
Kristina Burow ARCH Venture Partners Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »